Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability

Biochemical and Biophysical Research Communications

Volumn 430, Issue 3, 2013, Pages 975-980

  Mishra, Vinod K ^a   Palgunachari, Mayakonda N ^a   McPherson, David T ^b   Anantharamaiah, Gattadahalli M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Amphipathic helix; Apolipoprotein A I; High density lipoprotein; Lipid; Paraoxonase 1; Peptide

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1;

ARTICLE; DENSITY; DRUG ACTIVITY; DRUG SCREENING; DRUG STABILITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME STABILITY; MOLECULAR MODEL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTON NUCLEAR MAGNETIC RESONANCE;

AMINO ACID SEQUENCE; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; ENZYME STABILITY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHATIDYLCHOLINES; PROTEIN BINDING; RECOMBINANT PROTEINS;

EID: 84872498016     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.11.128     Document Type: Article

References (29)

1. Boden W.E., Pearson T.A. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am. J. Cardiol. 2000, 85:645-650.
2. Précourt L.P., Amre D., Denis M.C., Lavoie J.C., Delvin E., Seidman E., Levy E. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011, 214:20-36.
3. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
4. Shih D.M., Xia Y.R., Wang X.P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K.F., Berliner J.A., Witztum J.L., Lusis A.J. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 2000, 275:17527-17535.
5. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA, J. Am. Med. Assoc. 2008, 299:1265-1276.
6. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., Mackness M. Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circulation 2003, 107:2775-2779.
7. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001, 103:2283-2288.
8. Navab M., Reddy S.T., Van Lenten B.J., Anantharamaiah G.M., Fogelman A.M. The role of dysfunctional HDL in atherosclerosis. J. Lipid Res. 2009, 50:S145-S149.
9. Bouman H.J., Schomig E., van Werkum J.W., Velder J., Hackeng C.M., Hirschhauser C., Waldmann C., Schmalz H.G., ten Berg J.M., Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 2011, 17:110-116.
10. Soran H., Younis N.N., Charlton-Menys V., Durrington P. Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol. 2009, 20:265-274.
11. Podrez E.A. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol. 2010, 37:719-725.
12. Draganov D.I., La Du B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369:78-88.
13. Valiyaveettil M., Alamneh Y., Rezk P., Biggemann L., Perkins M.W., Sciuto A.M., Doctor B.P., Nambiar M.P. Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs. Biochem. Pharmacol. 2011, 81:800-809.
14. Gaidukov L., Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005, 44:11843-11854.
15. Gaidukov L., Viji R.I., Yacobson S., Rosenblat M., Aviram M., Tawfik D.S. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I3. Biochemistry 2009, 49:532-538.
16. Nayyar G., Mishra V.K., Handattu S.P., Palgunachari M.N., Shin R., McPherson D.T., Deivanayagam C.C.S., Garber D.W., Segrest J.P., Anantharamaiah G.M. Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides. J. Lipid Res. 2012, 53:849-858.
17. Mishra V.K., Anantharamaiah G.M., Segrest J.P., Palgunachari M.N., Chaddha M., Sham S.W.S., Krishna N.R. Association of a model class A (Apolipoprotein) amphipathic α-helical peptide with lipid. J. Biol. Chem. 2006, 281:6511-6519.
18. Mishra V.K., Palgunachari M.N., Krishna N.R., Glushka J., Segrest J.P., Anantharamaiah G.M. Effect of leucine to phenylalanine substitution on the nonpolar face of a class A amphipathic helical peptide on its interaction with lipid. J. Biol. Chem. 2008, 283:34393-34402.
19. Datta G., Chaddha M., Hama S., Navab M., Fogelman A.M., Garber D.W., Mishra V.K., Epand R.M., Epand R.F., Lund-Katz S., Phillips M.C., Segrest J.P., Anantharamaiah G.M. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 2001, 42:1096-1104.
20. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. USA 2004, 101:482-487.
21. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 1991, 19:100-106.
22. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B.G., McCarthy A., Toker L., Silman I., Sussman J.L., Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 2004, 11:412-419.
23. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL workspace. a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
24. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 2010, 21:229-238.
25. Davidson W.S., Silva R.A.G., Chantepie S., Lagor W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters. Arterioscler., Thromb., Vasc. Biol. 2009, 29:870-876.
26. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N. Human serum paraoxonase/arylesterase's retained hydrophobic N-Terminal Leader Sequence Associates with hdls by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler., Thromb., Vasc. Biol. 1999, 19:2214-2225.
27. Bashtovyy D., Jones M.K., Anantharamaiah G.M., Segrest J.P. Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J. Lipid Res. 2011, 52:435-450.
28. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 2002, 277:4301-4308.
29. Deakin S.P., Bioletto S., Bochaton-Piallat M.L., James R.W. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radical Biol. Med. 2011, 50:102-109.